Paper of the Month - August, 2011

0 rating

Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study.

Andersson M, Lidbrink E, Bjerre K et al.
The role of trastuzumab in the treatment of patients with metastatic breast cancer known to be HER2-positive was clearly established by Denis Slamon’s study with paclitaxel and Michel Marty’s study with docetaxel.


READER POLL

Breast Cancer Poll 1
What approach do you currently use for the treatment of patients with HER2-overexpressing metastatic breast cancer whose disease has progressed despite trastuzumab?






Powered by NetPolls

WEB LINKS

SUBMIT AN ARTICLE